In short
Clinical trials are studying Aon-D21 as an add-on treatment for severe community-acquired pneumonia. The main goal is to assess safety and tolerability, and the trial also looks at how well it works in adults admitted to intensive care or a similar unit.
Key points
- Aon-D21 is being studied in a Phase 2 clinical trial for severe community-acquired pneumonia. The trial tests Aon-D21 as an add-on treatment in patients admitted to an intensive care unit or a similar unit. Researchers compare it with placebo and focus mainly on safety and tolerability. The main endpoint measures the frequency, severity, and relatedness of treatment-emergent adverse events through Day 28. The available trial data show one completed study with 160 participants.
Trial overview
The available clinical trial data describe one study of Aon-D21 in people with severe community-acquired pneumonia, a serious lung infection that starts outside the hospital. The study is an interventional trial, which means researchers gave a study treatment and measured the results.
Who the study is for
This trial focused on patients with severe community-acquired pneumonia who were admitted to an intensive care unit or a similar high-acuity unit. In simple terms, this means the study population included very sick patients who needed close hospital monitoring and advanced care.
What the study is testing
The trial tested Aon-D21 as an add-on treatment, meaning it was used together with standard care rather than as a replacement. The study compared Aon-D21 with a placebo, which was a 5% glucose infusion that looked like the study treatment but did not contain Aon-D21.
The brief study summary says the main purpose was to assess the safety and tolerability of Aon-D21 in this patient group. Safety means checking for medical problems during the trial, and tolerability means how well patients can handle the treatment.
Trial phase and design
This was a Phase 2 study, which is an early stage that usually looks more closely at safety and whether there are early signs of benefit. The trial included 160 participants and is listed as completed.
What the study measures
The main endpoint was the frequency, severity, and relatedness of treatment-emergent adverse events until Day 28. An adverse event is any medical problem that happens during a study, and treatment-emergent means it starts or gets worse after treatment begins.
The study also tracked serious and non-serious adverse events, so researchers could see both major and less severe medical problems and judge whether they might be linked to Aon-D21. This kind of endpoint helps show whether the study treatment appears safe enough for further research.
Study status and size
The trial NCT05962606 is marked as completed. The enrollment was 160, which is the number of people who joined the study.
Only one trial was provided in the source data, so the current evidence base here is limited to this single Phase 2 study in severe community-acquired pneumonia.